Latest Breaking News On - Christina ohnsman - Page 1 : vimarsana.com

Objective Acuity announces successful pilot study in children with CLN2 Batten disease News provided by Share this article AUCKLAND, New Zealand, May 10, 2021 /PRNewswire/  Objective Acuity ( OAL ) today announced the completion of a pilot study using OAL s threshold visual acuity test for young children diagnosed with late-infantile neuronal ceroid lipofuscinosis Type 2 (CLN2 disease), a form of Batten disease. A prominent feature of CLN2 disease is vision loss, which typically develops when cognitive, motor and language impairments are already present. Measurement of visual acuity of those with the disease using standard methods is difficult and unreliable due to the age of those affected and their cognitive, language, and motor impairments.

Germany
Eppendorf
Nordrhein-westfalen
Hamburg
New-zealand
Adam-podmore
Christina-ohnsman
Senior-clinical-development
Objective-acuity
Senior-clinical-development-lead
Chief-executive-officer
Pad-pro